B
Bull
Bull · 25%BLUE
$16.32
情境價格
$4.970
0.000 (0.00%)收盤時
Loading chart…
- High
- 5.030
- Open
- 4.740
- VWAP
- 4.89
- Vol
- 1.25M
- Mkt Cap
- —
- Low
- 4.670
- Amount
- 6.09M
- EV/EBITDA, TTM
- -2.09
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. It markets three gene therapies: ZYNTEGLO (betibeglogene autotemcel, also known as beti-cel), SKYSONA (elivaldogene autotemcel, also known as eli-cel), and LYFGENIA (lovotibeglogene autotemcel, also known as lovo-cel). ZYNTEGLO is the first gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions. SKYSONA is used to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). LYFGENIA is used for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs).
Analyst Ratings (18)
+60.97% upside
Buy
12 Buy
5 Hold
1 Sell
Current: 4.97
最低
8.00
平均
8.00
最高
8.00
Barclays
Buy
$8
2025-03-31
Barclays
2025-03-31
目標價
$8
Buy
JP Morgan
Hold
—
2025-02-24
JP Morgan
2025-02-24
目標價
—
Hold
Wells Fargo
Hold
$5
2025-02-24
Wells Fargo
2025-02-24
目標價
$5
Hold
Barclays
Buy
$40
2024-12-31
Barclays
2024-12-31
目標價
$40
Buy
Barclays
Buy
$2
2024-11-15
Barclays
2024-11-15
目標價
$2
Buy
估值指標
The current forward P/E ratio for bluebird bio Inc (BLUE) is -0.38, compared to its 5-year average forward P/E of -1.62.
Alphio AI Price Scenarios for BLUE
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
事件時間軸
資訊
8.506-02Newsfilterbluebird bio Announces Completion of Acquisition by Carlyle and SK Capital
8.505-31Yahoo Financebluebird bio, Inc. (BLUE) Nears Acquisition by Carlyle and SK Capital
8.505-30SeekingAlphaCarlyle, SK Capital Partners disclose expected closing date of bluebird bio deal
- 8.505-30Newsfilter
Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer
8.505-30NASDAQ.COMCarlyle, SK Capital, Beacon Set To Close Bluebird Bio Acquisition
BLUE FAQ — answered by Alphio AI
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. It markets three gene therapies: ZYNTEGLO (betibeglogene autotemcel, also known as beti-cel), SKYSONA (elivaldogene autotemcel, also known as eli-cel), and LYFGENIA (lovotibeglogene autotemcel, also known as lovo-cel). ZYNTEGLO is the first gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions. SKYSONA is used to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). LYFGENIA is used for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
18 analysts cover BLUE: 12 rate it Buy, 5 Hold and 1 Sell. The average price target is 8.00.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。